SM
Therapeutic Areas
Apellis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SYFOVRE (pegcetacoplan) | Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration | Approved |
| EMPAVELI/Aspaveli (pegcetacoplan) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Approved |
| Pegcetacoplan | C3 Glomerulopathy (C3G) / Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 3 |
| Systemic C3 inhibitor (next-gen) | Undisclosed complement-mediated diseases | Preclinical |
| Intravitreal C3 inhibitor (next-gen) | Undisclosed retinal diseases | Preclinical |
Leadership Team at Apellis Pharmaceuticals
CF
Cedric Francois, MD, PhD
Co-Founder, Chief Executive Officer & President
CB
Caroline Baumal, MD
Chief Medical Officer
KB
Kelley Boucher
Chief People Officer
MD
Mark DeLong
Chief Business & Strategy Officer
PD
Pascal Deschatelets, PhD
Co-Founder & Chief Scientific Officer
LM
Leslie Meltzer, PhD
Chief Research & Development Officer
NN
Nur Nicholson
Chief Technical Operations Officer
TS
Timothy Sullivan
Chief Financial Officer
DW
David Watson, JD
General Counsel
GC
Gerald Chan, SD
Chairman of the Board